Stocks · News reference

RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

Aug 11, 2026, 3:14 PMBenzinga Newsdesk

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

The Motley FoolAug 28, 2026, 7:12 AMEric Volkman
Why Biohaven Stock Was Rocking the Market This Week
Biohaven announced a licensing and collaboration deal with SK Biopharmaceuticals worth up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim for focal epilepsy treatment. Additionally, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. These developments drove Biohaven stock up more than 16% week-to-date.
BHVN
BenzingaAug 26, 2026, 5:41 PMVandana Singh
Why Is Biohaven Stock Soaring Wednesday?
Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.
BHVN
BenzingaAug 26, 2026, 2:50 PMBenzinga Newsdesk
Biohaven shares are trading higher after the company announced that the U.S. District Court for the District of Delaware ruled in its favor in the case against Avilar Therapeutics. Biohaven announced a collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to the company's Kv7 ion channel platform.
BHVN
SEC EDGARAug 26, 2026, 10:38 AMSEC EDGAR
8-K filing — Biohaven Ltd. (BHVN)
Filed: 2026-08-26 AccNo: 0001935979-26-000072 Size: 890 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
BHVN